Diabetes News
2017-11-29
California Partners with Civica Rx to Make More Affordable Insulin
California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORE
Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORE
Novo Nordisk to Slash Insulin Prices by over 65%
Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MORE
Freestyle Libre 2 and 3 Receive FDA Clearance for Integration with Automated Insulin Delivery Systems
Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!MORE
$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions
On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MORE
FDA Approves Teplizumab to Delay Onset of Type 1 Diabetes
Teplizumab binds to certain immune system cells and delays the progression of T1D.MORE
This New App is Designed to Make Tracking Your Insulin Easier
If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORE
Say Hello to BeyondType2.org in French, German and Italian!
BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MORE
The Future of Insulin — Will It Be Affordable for the People Who Need It?
Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MOREDiabetes + Dementia: Using Nasal Insulin to Improve Brain Function
With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
Women + Exercise: It’s Complicated
Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MORE
Reaching Everyone — Health Disparities in Physical Activity
People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MOREAnother Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
Race, Racism, and Diabetes Research
Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MOREMounjaro: Its Powerful Potential to Treat Type 2 Diabetes & Obesity
Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MOREResearch: Practical Use of Closed-Loop Insulin Pumps
Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MOREAccess to Insulin: In the United States
Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MOREAccess to Insulin: In Low-Income Countries
In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity
The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE
Stem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270
A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MORE
Coverage of Dexcom G6 CGM Now Improved with TRICARE
TRICARE healthcare members can now receive the Dexcom G6 continuous glucose monitor (CGM) under pharmacy benefits.MORE
The Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE
FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE
Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings
The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time
The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE
Omnipod 5 Receives FDA Approval
Omnipod 5, a closed-loop tubeless insulin pump with smartphone control that integrates with the Dexcom G6 continuous glucose monitor, has now received FDA approval.MORE
Inside the Drug Pricing Investigation from the House Oversight and Reform Committee
The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MORE
The Potential Impact of Build Back Better on American Healthcare
Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs
Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE
A Win for T1D in California: Senate Bill 97 Signed Into Law
The bill requires type 1 diabetes informational materials to be developed for the parents and guardians of pupils in California schools.MORE
Beyond Type 1 Launches Web Platform in Arabic
Diabetes information, stories, and news are now available in Arabic at ar.beyondtype1.org.MORE
COVID-19 Vaccines For Kids Ages 5 to 11 With Diabetes: What to Know
COVID-19 vaccines are now available for kids age 5+! Learn about safety and managing side effects for kids with type 1 diabetes.MORE
Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%
The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORE
Lilly Announces Lower List price for Insulin Lispro
The company will lower the list price of the generic version of Humalog in the U.S. by an additional 40 percent starting January 1, 2022.MORE
Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit
Lilly announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes
Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
Yarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico
Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
Overweight Adults to Now Be Screened for Type 2 Diabetes At 35
The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MORE
Pandemic Homelessness Disproportionately Impacts People With Diabetes
An American Diabetes Association report found that pandemic homelessness hit people with diabetes 48 times harder.MORE
Abbott’s FreeStyle Libre 2 App Receives FDA Clearance
On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE
FDA Approves Senza®, Nevro’s High Frequency Spinal Cord Stimulation Therapy For PDN
The Senza System has been approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy.MORE
Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin
Semglee becomes the first interchangeable biosimilar insulin product for the treatment of type 1 and type 2 diabetes.MORE
Providing Culturally Sensitive LGBTQ+ Diabetes Health Care
Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE
High Risk Pregnancy – Mitigating Risks for Type 1 Diabetes + Black Maternal Health Outcomes
Ariel Lawrence, a diabetes advocate and Black mother with type 1 diabetes, shares how she navigated her pregnancy. MORE
Addressing Disparities in Pediatric Diabetes Treatment In Philadelphia
Terri Lipman shares how incorporating community health workers can tackle disparities in pediatric diabetes treatment. MORE
FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D
The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE
Combating Diabetes Disparities Among The Hispanic Population
At ADA 2021, David Marrero discusses how culturally tailored care can combat diabetes disparities among the Hispanic population.MORE
Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE
Preliminary Findings On Depression Among African American and Latino Parents of Children With T1D
Samantha Carreon shares preliminary data on the TEAM study which found higher rates of depression among African American and Latino parents.MORE
Making Broadway More Accessible With JP Qualters
JP Qualters shares his experience on Broadway as a person living with type 1 diabetes and his aspirations for the theater industry.MORE
Zegalogue® Is Now Commercially Available In The United States
Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE
Medicare Loosens Restrictions on Continuous Glucose Monitor Coverage
Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
Supreme Court Votes To Keep The ACA Intact
The Affordable Care Act (ACA) provides health care to millions of Americans. The Supreme Court voted 7-2 to keep the ACA intact.MORE
COVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color
Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MORE
Michelle L. Litchman Focuses On Diabetes Program Accessibility For People Who Are Deaf
Michelle L. Litchman was named a Betty Irene Moore Nurse Fellow. She will focus on diabetes program accessibility for people who are deaf.MORE
Test Strip Subscription Guide
We compiled a rundown of popular companies that offer test strip subscription services and researched each of them to give you some important info.MORE
Omnipod 5 Pivotal Trial Data Published
Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
Breaking News From ATTD 2021
This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
Survey Finds the Pandemic Increased Mental Health Concerns Among People With Diabetes
Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORE
FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 Diabetes
Teplizumab is an investigational candidate proven to delay the onset of type 1 diabetes. The FDA advisory committee reviews its efficacy.MORE
Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace
Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA
Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE
Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research
Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE
Type 1 Diabetes + Ramadan: Here’s How a Few People Are Observing
People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE
The PROTECT Study
The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE
Chris Hahm’s Uphill Battle: The Severe Underfunding of AAPI Diabetes Research
H. Chris Hahm shares her challenges of conducting diabetes research focused on the AAPI community, research that is severely underfunded.MORE
CDC and FDA Call for Pause on Johnson & Johnson Vaccine
After six cases of rare blood clots, the CDC and FDA has advised healthcare professionals to pause on distributing the Johnson and Johnson vaccine.MORE
FDA Approves New Glucagon Option from Zealand Pharma
Available in June 2021, the FDA approved Zealand Pharma’s Zeagalogue, a new form of glucagon for people with insulin-dependent diabetes.MORE
Two Pillars in the Diabetes Community Unite to Serve Millions Living with Diabetes
The partnership will feature combined resources, strategies, and tactics to better serve people living with type 1 diabetes, type 2 diabetes, and prediabetes.MORE
JDRF Announces New Center of Excellence to Advance T1D Research
On February 23, 2021, JDRF announced the launch of the JDRF Center of Excellence in collaboration with the Harvard Stem Cell Institute in New England.MORE
Get the Facts on Insulin Pricing + The Presidential Transition
A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE
New Year, New Administration: What’s Coming For US Healthcare Policy
With a new governmental administration, it is likely we will see notable and impactful movement in healthcare policy. What can we expect? MORE
Congress Renews Funding for Special Diabetes Program
On Dec 22, 2020, Congress renewed the Special Diabetes Program, providing $150 million annually in type 1 diabetes research funding until 2023MORE
JDRF Launches Program to Advance Universal Screening for Type 1 Diabetes
T1Detect is a new screening initiative designed to make early detection of type 1 diabetes easier and more accessible to a broad population. MORE
Diabetes + COVID Vaccines: What You Need to Know
If you have diabetes, here’s everything you need to know about the COVID-19 vaccines.MORE
Amazon Launches Online Pharmacy
Amazon Pharmacy, launched on November 17, delivers medications and prescription refills - such as insulin - with Prime membership 2-day shipping.MORE
Fourth Major Insulin Manufacturer Enters US Market with Semglee Launch
Semglee (insulin glargine), from Mylan and Biocon, is now available by prescription in the United States in vial and pre-filled pen presentations.MORE
With SAG-AFTRA Healthcare Changes, Can T1Ds Stay in the Arts?
With recently announced SAG-AFTRA healthcare changes, do the majority of people with T1D realistically have the option to choose a profession in the arts? MORE
JDRF Announces Updated Strategy, Renewed Focus in Light of COVID-19
Amidst COVID-19, JDRF prioritizing work in their portfolio that they see as having the highest likelihood for cures and life changing advances for diabetes.MORE
Study Links COVID-19 to Increased Rates of DKA at Diagnosis in Children
In a German study from March to May 2020, nearly half of minors had DKA at type 1 diabetes diagnosis - double previous years - amidst COVID-19.MORE
United Healthcare to Begin Covering Tandem Insulin Pumps
On July 1, 2020, United Healthcare (UHC) announced they will begin covering the Tandem t:slim X2 insulin pump, a departure from UHC’s four-year policy to only provide health insurance coverage for M...MORE
Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab Trial
Half of those treated with teplizumab remain diabetes-free, compared to 22% of those taking placebo, and the delay in diabetes onset was close to 3 years.MORE
Disparities in Diabetes and Diabetes Care—What Can We Do About It?
At this ADA 2020 session, systemic racism and implicit bias were clear contributors to poor health and healthcare outcomes for Black and Latinx communities.MORE
T1D Exchange + Beyond Type 1 Marathon Study Presented at ADA 2020
The Beyond Type Run team has taken on 26.2 miles to not only raise awareness and funds for T1D, but to provide crucial data for a study pertaining to management of Type 1 before, during, and after a m...MORE
One Drop Announces New Overnight Hypo Predictions and Long-Term Health Forecasts at ADA 2020
One Drop unveiled new AI-powered predictions for blood glucose, A1C, blood pressure, and weight up to six months in advanceMORE
FreeStyle Libre 2 Approved for Use in U.S.
Those living with type 1 diabetes in the U.S. now have the opportunity to manage their disease utilizing the perks of Abbott’s Freestyle Libre 2. MORE
Closed Loop Updates: Omnipod Horizon and Medtronic 780G data presented at ADA 2020
Data from four new clinical trials involving Hybrid Closed Loop systems, Medtronic 780G and Omnipod 5 Powered by Horizon was presented at ADA 2020.MORENew Research Resource from Beyond Type 1 Aims to Bridge the Gap Between Science and Community
A new collection of resources shared today by Beyond Type 1 breaks down the most impactful current type 1 diabetes research into quick and easy to understand information. MORE
Medicare Part D Senior Savings Model Caps Insulin Costs at $35 per Month
The Senior Savings Model caps out of pocket insulin costs at $35 per month for seniors enrolled in eligible plans.MORE
England’s NHS Releases Study on Risk of COVID-19 for People with Diabetes
This week, the National Health Service (NHS) in England released the first study of its kind, breaking down COVID-19 mortality risk by type of diabetes.MOREArmed For Diabetes Created to Help Veterans With Resources For Better Diabetes Management
Armed for Diabetes highlights continuous glucose monitoring prescribing guidelines for veterans.MORE
Roche Offers Free Access to mySugr Pro During COVID-19
With the rise of telemedicine during COVID-19, free access to mySugr Pro will help people stay connected to their healthcare team. MORE
Minnesota Passes the Alec Smith Insulin Affordability Act
The Alec Smith Insulin Affordability Act was signed into law in Minnesota, providing MN residents options for emergency and ongoing insulin access for those who qualify.MORE
Novo Offers Free 90-Day Insulin Supply to People Recently Uninsured Due to COVID-19
Novo Nordisk announces program offering a free 90-day supply of Novo Nordisk insulin for those who have recently lost their health insurance coverage due to a change in job status because of COVID-19....MORE
Beyond Type 1 Asks Congress To Support Expanded Paid Leave For Chronic Conditions During COVID-19
Beyond Type 1 joined 156 other organizations in urging Congress to expand paid leave for those with chronic illness, who are at higher risk for complications from COVID-19.MORE
FreeStyle Libre Approved by FDA for Hospitalized Patients During COVID-19 Pandemic
Abbott's FreeStyle Libre 14 day system will allow doctors to remotely monitor their patient's glucose levels. MORE
New Program Offers $35 Monthly Copays for Lilly Insulins
Eli Lilly announced a new program that allows people in the US to fill their monthly prescription of Lilly insulin for $35 per month with a copay card.MORE
Senseonics Suspends Commercial US Sales of Eversense in Response to COVID-19
On March 26, Senseonics suspended all commercial sales of the Eversense continuous glucose monitor (CGM) in the United States.MORE
New Insulin Approval Pathway Could Increase Competition
The new regulatory pathway “is expected to increase patient access, adding more choices and potentially reducing costs of these vital therapies.”MORE
The Power in Numbers: Change.org’s Affordable Insulin For All Movement
As insulin prices continue to increase in the United States, Change.org is equipping those affected with the tools to speak out.MORE
